|
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
PR Newswire (press release) Palatin has started discussions with a number of potential development and marketing partners for PL-3994 for acute asthma, which would include the proof-of-concept human trial for asthma using a subcutaneously administered formulation and development … Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript |
View full post on asthma – Google News